The recombinant humanized anti-CD16 monoclonal antibody is a high-affinity therapeutic agent produced via CHO stable cells, specifically targeting the membrane-proximal epitope of FcγRIII (CD16). By precisely mimicking the spatial conformation of natural IgG-Fc binding, it activates Syk/ZAP70 kinase-dependent phosphorylation cascades, triggering calcium influx and PI3K-AKT/mTOR-MAPK signaling pathways in NK cells to enhance antibody-dependent cellular cytotoxicity (ADCC) and stimulate secretion of proinflammatory cytokines such as IFN-γ and TNF-α.
In ex vivo NK cell expansion systems this antibody significantly improves CD107a degranulation efficiency and proliferation rates while synergizing with IL-2/IL-15 to maintain metabolic adaptability of effector memory NK cell subsets (CD56dim/CD16+).
Manufactured using animal component-free culture media and multi-step chromatographic purification, the product complies with release specifications through stringent controls on host DNA residuals, host protein contaminants, and endotoxin levels. It is designed for applications in CAR-NK development, bispecific antibody-engaged immune cell therapies, and tumor vaccine adjuvant systems.